Profile data is unavailable for this security.
About the company
Azitra, Inc. is an early-stage clinical biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. The Company’s product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
- Revenue in USD (TTM)572.70k
- Net income in USD-12.40m
- Incorporated2014
- Employees10.00
- LocationAzitra Inc21 Business Park Drive, Suite 6BRANFORD 06405United StatesUSA
- Phone+1 (203) 489-0183
- Fax+1 (302) 636-5454
- Websitehttps://azitrainc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProtoKinetix, Inc. | 0.00 | -400.47k | 5.65m | 0.00 | -- | 14.23 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0011 | 0.00 | -- | -- | -- | -88.14 | -696.88 | -101.62 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 5.65m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 5.66m | 3.00 | 3.84 | -- | 223.07 | 20.12 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| HST Global Inc | 0.00 | -146.22k | 5.67m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
| Azitra Inc | 572.70k | -12.40m | 5.77m | 10.00 | -- | 1.33 | -- | 10.07 | -2.87 | -2.87 | 0.0492 | 0.1501 | 0.0977 | -- | 11.54 | 57,270.00 | -200.61 | -- | -287.43 | -- | -- | -- | -2,053.34 | -- | -- | -129.02 | 0.0085 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Biofrontera Inc | 33.25m | -23.09m | 5.80m | 85.00 | -- | -- | -- | 0.1745 | -12.47 | -12.47 | 16.84 | -0.3627 | 0.9995 | 2.50 | 5.75 | 391,200.00 | -69.40 | -- | -144.06 | -- | 48.99 | -- | -69.44 | -- | 0.944 | -3.55 | 4.63 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 5.81m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Kineta Inc | 5.16m | -17.89m | 5.83m | 11.00 | -- | -- | -- | 1.13 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Hoth Therapeutics Inc | 0.00 | -7.70m | 5.87m | 2.00 | -- | 0.6747 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
| Healthy Extracts Inc | 2.49m | -2.47m | 5.93m | -- | -- | 6.19 | -- | 2.38 | -0.8588 | -0.8588 | 0.8611 | 0.3231 | 0.918 | 0.4921 | 36.50 | -- | -91.32 | -53.78 | -174.02 | -146.65 | 65.90 | 45.68 | -99.48 | -87.53 | 0.1636 | -9.72 | 0.5245 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.28m | 5.94m | 4.00 | -- | 0.6466 | -- | 659.83 | -3.74 | -3.74 | 0.0064 | 6.81 | 0.0007 | 0.4291 | -- | 2,250.00 | -42.47 | -110.00 | -43.88 | -- | 60.00 | 65.82 | -58,624.33 | -7,961.14 | 23.53 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -12.23m | 5.96m | 5.00 | -- | 0.2377 | -- | -- | -37.38 | -37.38 | 0.00 | 21.08 | 0.00 | -- | -- | 0.00 | -13.75 | -40.33 | -15.54 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Adial Pharmaceuticals Inc | 0.00 | -11.24m | 6.01m | 4.00 | -- | 0.9406 | -- | -- | -6.01 | -3.75 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -212.33 | -182.35 | -273.26 | -235.45 | -- | -- | -- | -- | -- | -20.20 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Altium Capital Management LPas of 31 Mar 2024 | 493.15k | 1.71% |
| Sabby Management LLCas of 31 Mar 2024 | 425.26k | 1.48% |
| Warberg Asset Management LLCas of 31 Mar 2024 | 300.50k | 1.04% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 199.40k | 0.69% |
| Precept Management LLCas of 30 Sep 2023 | 50.00k | 0.17% |
| XTX Markets LLCas of 31 Mar 2024 | 24.59k | 0.09% |
| Citadel Securities LLCas of 31 Mar 2024 | 14.28k | 0.05% |
| Tower Research Capital LLCas of 31 Mar 2024 | 6.78k | 0.02% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.05k | 0.01% |
| RBC Dominion Securities, Inc.as of 31 Mar 2024 | 79.00 | 0.00% |
